Rhinitis Clinical Trial
Official title:
Observational Study Evaluating the Safety and Efficacy of Desloratadine Syrup for Perennial Allergic Rhinitis in Indonesian Pediatric Patients
NCT number | NCT00704769 |
Other study ID # | P04299 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | May 2005 |
Est. completion date | December 2007 |
Verified date | February 2022 |
Source | Organon and Co |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Evaluate the safety and general clinical response of desloratadine syrup in the relief of symptoms associated with perennial allergic rhinitis in Indonesian pediatric patients.
Status | Completed |
Enrollment | 591 |
Est. completion date | December 2007 |
Est. primary completion date | December 2007 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 2 Years to 11 Years |
Eligibility | Inclusion Criteria: - Children patients of both sexes aged between 2-11 years, of either gender and any race - Unequivocal history of perennial allergic rhinitis, including nasal congestion, sneezing, rhinorrhea, pruritus, and lacrimation - Minimum score for inclusion: 10 - Capable of complying with the dosing regimen - Free of any clinically significant disease (other than allergic rhinitis) - Antihistamine must be justified by investigating doctor Exclusion Criteria: - Patients with asthma who require chronic use of inhaled or systemic corticosteroids - History of frequent, clinically significant sinusitis or chronic purulent postnasal drip - Patients with rhinitis medicamentosa - History of hypersensitivity to desloratadine or any of its excipients - Doctor deems unsuitable |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Organon and Co |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Adverse Events | An adverse event was defined in the protocol to include any untoward medical occurrence or unfavorable and unintended sign in a subject administered a pharmaceutical product (at any dose). Additionally, any event that is associated with or observed in conjunction with a product overdose (whether accidental or intentional) or a product abuse and/or withdrawal were also considered an adverse event. The investigator assessed the relationship of any adverse event as either unlikely, possibly, or probably related to the use of study drug based on available information and protocol guidelines. | Minimum of 7 days after initiation of desloratadine | |
Primary | General Clinical Response of Desloratadine Syrup Based on the Physician's Judgments | Physicians judged the subjects as good, excellent, fair, or poor. | Minimum of 7 days after initiation of desloratadine |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02340130 -
Safety, Tolerability and Efficacy of the Depigmented Modified Allergen Extract of Two Mites in Subjects With Allergic Rhinitis or Rhinoconjunctivitis, With Controlled Allergic Asthma
|
Phase 2 | |
Completed |
NCT02360072 -
Airway Inflammation and Bronchial Hyperresponsiveness in Rhinitic Children With or Without Asthma
|
||
Completed |
NCT01118312 -
Study of Asthma and Nasal Steroids
|
Phase 4 | |
Completed |
NCT00762567 -
Phenylephrine Pediatric Pharmacokinetic Study
|
Phase 1 | |
Completed |
NCT00541255 -
A Long-Term Examination of Asthma From Childhood Through Adolescence
|
||
Completed |
NCT00279916 -
Short Term Relief of Eustachian Tube Dysfunction and Serous Otitis Media Using Intranasal Steroid Sprays
|
Phase 3 | |
Completed |
NCT00524836 -
Efficacy and Safety of Levocetirizine Versus Loratadine for the Treatment of Perennial Allergic Rhinitis
|
Phase 3 | |
Completed |
NCT00963573 -
Efficacy & Safety of Loratadine-Betamethasone Oral Solution for Treatment of Severe Perennial Allergic Rhinitis in Children (Study P03428)
|
Phase 4 | |
Completed |
NCT00521131 -
Evaluation of Efficacy and Safety of Levocetirizine to Subjects With Perennial Allergic Rhinitis to House Dust Mites
|
Phase 4 | |
Completed |
NCT04132570 -
A Study of Intranasal Budesonide Aqueous Spray for Treatment of Rhinitis During Periods of High Airborne Pollution
|
Phase 4 | |
Completed |
NCT02784262 -
Botulinum Toxin Type A Block of the Sphenopalatine Ganglion in Chronic Rhinosinusitis With Nasal Polyposis
|
Phase 2 | |
Completed |
NCT02596321 -
A Study Investigating the Immunologic Effects and Safety of 60-day Treatment of the ALK HDM Tablets in Adult Subjects With HDM-Induced Allergic Rhinitis and/or Atopic Asthma
|
Phase 3 | |
Terminated |
NCT02630472 -
Topical Irrigation Therapy for CRS
|
Phase 1/Phase 2 | |
Completed |
NCT02279706 -
Korean Linguistic Adaptation of Rhinitis Controlled Assessment Test
|
N/A | |
Completed |
NCT01971086 -
Treatment With Rhinospray Plus in Patients With Acute Rhinitis in the Everyday Curative Routine in Hungary
|
N/A | |
Completed |
NCT01771120 -
Control and Burden of Asthma and Rhinitis
|
N/A | |
Completed |
NCT01469234 -
A Study of Onset of Action of Loratadine and Fexofenadine in Participants With Seasonal Allergic Rhinitis (P08712)
|
Phase 4 | |
Withdrawn |
NCT01177852 -
Evaluation of Efficacy and Safety in Control Cough and the Relief of Nasal Symptoms in Children 2-12 Years Old,Suffering From Cough and Acute Rhinitis
|
Phase 3 | |
Completed |
NCT02879929 -
Development and Validity of the DyNaChron Questionnaire for Chronic Nasal Dysfunction
|
N/A | |
Completed |
NCT00724698 -
Evaluation of Desloratadine When Used in Patients With Either Allergic Rhinitis or Chronic Idiopathic Urticaria
|